Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved..
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 19(2020), 11 vom: 20. Nov., Seite 102671 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gauckler, Philipp [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 06.01.2021 Date Revised 06.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2020.102671 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315135425 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315135425 | ||
| 003 | DE-627 | ||
| 005 | 20231225154244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2020.102671 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315135425 | ||
| 035 | |a (NLM)32942039 | ||
| 035 | |a (PII)S1568-9972(20)30246-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gauckler, Philipp |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2021 | ||
| 500 | |a Date Revised 06.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Focal segmental glomerulosclerosis | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Long-term remission | |
| 650 | 4 | |a Minimal change disease | |
| 650 | 4 | |a Nephrotic syndrome | |
| 650 | 4 | |a Rituximab | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Shin, Jae Il |e verfasserin |4 aut | |
| 700 | 1 | |a Alberici, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Audard, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Bruchfeld, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Busch, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Chee Kay |e verfasserin |4 aut | |
| 700 | 1 | |a Crnogorac, Matija |e verfasserin |4 aut | |
| 700 | 1 | |a Delbarba, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Eller, Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Faguer, Stanislas |e verfasserin |4 aut | |
| 700 | 1 | |a Galesic, Kresimir |e verfasserin |4 aut | |
| 700 | 1 | |a Griffin, Siân |e verfasserin |4 aut | |
| 700 | 1 | |a Hrušková, Zdenka |e verfasserin |4 aut | |
| 700 | 1 | |a Jeyabalan, Anushya |e verfasserin |4 aut | |
| 700 | 1 | |a Karras, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a King, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kohli, Harbir Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Maas, Rutger |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseev, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Odler, Balazs |e verfasserin |4 aut | |
| 700 | 1 | |a Pepper, Ruth J |e verfasserin |4 aut | |
| 700 | 1 | |a Quintana, Luis F |e verfasserin |4 aut | |
| 700 | 1 | |a Radhakrishnan, Jai |e verfasserin |4 aut | |
| 700 | 1 | |a Ramachandran, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Salama, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Segelmark, Mårten |e verfasserin |4 aut | |
| 700 | 1 | |a Tesař, Vladimír |e verfasserin |4 aut | |
| 700 | 1 | |a Wetzels, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Willcocks, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Windpessl, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Zand, Ladan |e verfasserin |4 aut | |
| 700 | 1 | |a Zonozi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Kronbichler, Andreas |e verfasserin |4 aut | |
| 700 | 0 | |a RITERM study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 19(2020), 11 vom: 20. Nov., Seite 102671 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:11 |g day:20 |g month:11 |g pages:102671 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2020.102671 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 11 |b 20 |c 11 |h 102671 | ||